The Scientist

» cancer and disease/medicine

Most Recent

image: First Drug from GM Plant Approved

First Drug from GM Plant Approved

By | May 4, 2012

A human enzyme grown in carrot cells will treat patients with Gaucher disease.

10 Comments

image: Nervous Mice Get Worse Cancer

Nervous Mice Get Worse Cancer

By | May 3, 2012

Anxious mice are more likely to come down with aggressive skin cancer than those who show less stress on behavioral tests.

0 Comments

image: FDA Disputes Data Under-Reporting

FDA Disputes Data Under-Reporting

By | May 2, 2012

The FDA and NIH dispute reports that clinical trial data is being under-reported.

0 Comments

image: Telomere Basics

Telomere Basics

By | May 1, 2012

Telomeres are repetitive, noncoding sequences that cap the ends of linear chromosomes. They consist of hexameric nucleotide sequences (TTAGGG in humans) repeated hundreds to thousands of times. 

4 Comments

Contributors

May 1, 2012

Meet some of the people featured in the April 2012 issue of The Scientist.

0 Comments

image: Designing Transition-State Inhibitors

Designing Transition-State Inhibitors

By | May 1, 2012

A transition-state mimic has the power to bind an enzyme at its tipping point as strongly as any available inhibitor and more strongly than most, preventing enzymatic activity. 

0 Comments

image: Treating Fat with Fat

Treating Fat with Fat

By | May 1, 2012

Is brown fat ready for therapeutic prime time?

22 Comments

image: Tumor Turnabout

Tumor Turnabout

By | May 1, 2012

A cytokine involved in suppressing the immune system may actually activate it to kill cancer cells.

4 Comments

image: Data Diving

Data Diving

By | May 1, 2012

What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.

28 Comments

image: Freezing Time

Freezing Time

By | May 1, 2012

Targeting the briefest moment in chemistry may lead to an exceptionally strong new class of drugs.

15 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech